Jiang Z F, Li J B
Department of Breast Cancer, the Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100071, China.
Department of Medical Molecular Biology, Institute of Biotechnology, Academy of Military Medical Sciences, Beijing 100071, China.
Zhonghua Wai Ke Za Zhi. 2020 Feb 1;58(2):85-90. doi: 10.3760/cma.j.issn.0529-5815.2020.02.002.
In the past two decades, with the introduction of NCCN guidelines, the establishment of a standardized diagnosis and treatment system for breast cancer had begun. The Chinese version of the NCCN guidelines, which combines international standards and Chinese characteristics, was then developed to guide clinical practice. Since 2011, Chinese experts have entered St. Gallen International Expert Consensus Group, and to introduce the latest therapy concepts. On this basis, the Chinese Society of Clinical Oncology has developed guidelines for diagnosis and treatment in line with product accessibility and expert opinions to help clinicians choose the best treatment option. The latest Chinese Society of Clinical Oncology Breast Cancer Guideline will further contribute to the establishment of a standardized diagnosis and treatment system for breast cancer.
在过去二十年里，随着美国国立综合癌症网络（NCCN）指南的引入，乳腺癌标准化诊断和治疗体系开始建立。随后制定了结合国际标准和中国特色的NCCN指南中文版，以指导临床实践。自2011年以来，中国专家加入了圣加仑国际专家共识小组，以引入最新的治疗理念。在此基础上，中国临床肿瘤学会根据产品可及性和专家意见制定了诊断和治疗指南，以帮助临床医生选择最佳治疗方案。最新的中国临床肿瘤学会乳腺癌指南将进一步推动乳腺癌标准化诊断和治疗体系的建立。
